Aspergillosis Clinical Trial
Official title:
Prevalence of Chronic Pulmonary Aspergillosis and Antifungal Drug Resistance of Aspergillus Spp. in Pulmonary Tuberculosis Patients in Uzbekistan
Pulmonary tuberculosis (PTB) is the most common cause of lung destruction, contributing to coinfections development, and Aspergillosis spp. is one of the most important. Diagnosis of chronic pulmonary aspergillosis (CPA) in PTB patients is difficult due to similarity of clinical and radiological data, especially in resource-constrained settings. Differentiation of PTB patients with singling out a group with a higher Aspergillus IgG level during the initial examination will help physicians to orient to further examination of CPA. Objectives: to determine the prevalence of aspergillosis in Koch's bacillus-positive and Koch's bacillus-negative PTB patients and antifungal resistance of Aspergillus species isolates in Central Asia countries.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2030 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 90 Years |
Eligibility | Inclusion Criteria: - Pulmonary tuberculosis patients (smear-positive) - Pulmonary tuberculosis patients (smear - negative) Exclusion Criteria: - neutropenia - severe immunosuppression caused by cancer chemotherapy - hematopoietic stem cell or solid organ transplantation - HIV infected individuals |
Country | Name | City | State |
---|---|---|---|
Uzbekistan | Research institute of epidemiology, microbiology and infectious diseases | Tashkent | Uchtepa |
Lead Sponsor | Collaborator |
---|---|
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan |
Uzbekistan,
Toychiev A, Belotserkovets V, Ignat'ev N, Madrakhimov S, Shaislamova M, Osipova S. Prevalence of chronic pulmonary aspergillosis and the antifungal drug resistance of Aspergillusspp. in pulmonary tuberculosis patients in Uzbekistan. Trop Doct. 2022 Oct;52 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Aspergillus IgG | ELISA of serum of pulmonary tuberculosis patients. | 2020-2025 | |
Primary | Aspergillus sp. | Isolation of Aspergillus sp. among pulmonary tuberculosis patients | 2020-2025 | |
Primary | Antimicrobial resistance | Detection of antimicrobial resistance of fungi | 2020-2025 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT01887457 -
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
|
Phase 2 | |
Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
Enrolling by invitation |
NCT01617759 -
Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
|
||
Terminated |
NCT03905447 -
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
|
Phase 2 | |
Recruiting |
NCT04744454 -
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
|
||
Completed |
NCT02715570 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
|
Phase 1 | |
Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
Completed |
NCT04935463 -
Mucormycosis in COVID-19
|
||
Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
Completed |
NCT00473252 -
Surveillance of Fungal Infections During Construction Activity
|
N/A | |
Completed |
NCT00037206 -
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
|
Phase 2/Phase 3 | |
Completed |
NCT04818853 -
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
|
||
Completed |
NCT00412893 -
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
|
Phase 3 | |
Recruiting |
NCT06135597 -
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
|
||
Terminated |
NCT02646800 -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
|
Phase 4 | |
Completed |
NCT00854607 -
An Observational Study of Fungal Biomarkers (MK-0000-089)
|
N/A | |
Completed |
NCT00388167 -
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
|
Phase 4 | |
Completed |
NCT05065658 -
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
|
||
Completed |
NCT00005912 -
Voriconazole to Prevent Systemic Fungal Infections in Children
|
Phase 1 |